BNP Paribas Financial Markets Purchases 4,796 Shares of Cardlytics, Inc. (NASDAQ:CDLX)

BNP Paribas Financial Markets grew its position in Cardlytics, Inc. (NASDAQ:CDLX) by 32.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 19,745 shares of the company’s stock after purchasing an additional 4,796 shares during the period. BNP Paribas Financial Markets’ holdings in Cardlytics were worth $63,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GSA Capital Partners LLP grew its position in shares of Cardlytics by 1,273.2% in the 3rd quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock valued at $1,223,000 after purchasing an additional 354,474 shares during the period. Renaissance Technologies LLC lifted its stake in Cardlytics by 711.9% in the second quarter. Renaissance Technologies LLC now owns 351,035 shares of the company’s stock valued at $2,882,000 after buying an additional 307,800 shares in the last quarter. Marshall Wace LLP lifted its stake in Cardlytics by 6.8% in the second quarter. Marshall Wace LLP now owns 814,281 shares of the company’s stock valued at $6,685,000 after buying an additional 52,081 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of Cardlytics in the third quarter valued at approximately $153,000. Finally, Acorn Financial Advisory Services Inc. ADV increased its position in shares of Cardlytics by 40.5% during the third quarter. Acorn Financial Advisory Services Inc. ADV now owns 164,409 shares of the company’s stock worth $526,000 after acquiring an additional 47,358 shares in the last quarter. 68.10% of the stock is owned by institutional investors.

Cardlytics Trading Up 0.6 %

Shares of NASDAQ:CDLX opened at $3.55 on Friday. The company’s 50-day moving average price is $3.93 and its two-hundred day moving average price is $5.30. Cardlytics, Inc. has a one year low of $2.89 and a one year high of $20.52. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.18 and a quick ratio of 1.18. The stock has a market capitalization of $180.42 million, a PE ratio of -0.58 and a beta of 1.53.

Cardlytics (NASDAQ:CDLX) last released its earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.18. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The business had revenue of $67.06 million for the quarter, compared to analyst estimates of $57.77 million. During the same quarter in the prior year, the company posted ($0.26) earnings per share. Cardlytics’s revenue was down 15.1% on a year-over-year basis. On average, equities analysts forecast that Cardlytics, Inc. will post -1.52 EPS for the current fiscal year.

Insider Transactions at Cardlytics

In related news, CFO Alexis Desieno sold 25,118 shares of Cardlytics stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $3.43, for a total transaction of $86,154.74. Following the completion of the transaction, the chief financial officer now owns 116,481 shares in the company, valued at approximately $399,529.83. This trade represents a 17.74 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Amit Gupta sold 22,607 shares of the business’s stock in a transaction that occurred on Thursday, October 24th. The stock was sold at an average price of $3.85, for a total value of $87,036.95. Following the transaction, the chief executive officer now directly owns 178,519 shares in the company, valued at approximately $687,298.15. This trade represents a 11.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 68,691 shares of company stock worth $237,767 in the last 90 days. Corporate insiders own 4.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Evercore ISI assumed coverage on shares of Cardlytics in a research note on Friday, October 11th. They issued an “in-line” rating and a $4.00 target price for the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Cardlytics in a research report on Thursday, November 7th. Finally, Craig Hallum upgraded Cardlytics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $6.92.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.